Scholarlink

<p>The landscape of cancer treatment has shifted from histology-specific to tissue-agnostic approaches, targeting molecular alterations regardless of tumor origin. Currently, six pan-cancer biomarkers—NTRK, BRAF V600E, RET, HER2-positive, MSI-high, and TMB-high—along with nine molecularly targeted therapies have expanded treatment options across diverse malignancies. This review examines each biomarker’s molecular basis, prevalence across tumor types, and corresponding FDA-approved therapies. Additionally, emerging candidates—including FGFR, ALK, MET, ROS1, NRG1, PIK3CA, AKT, KRAS G12C, HER2 mutations, HER2-low/ultralow, B7-H3, and tumor-infiltrating lymphocytes (TILs)—are explored. While these biomarkers represent a paradigm shift in oncology, their integration into clinical practice requires overcoming challenges related to tumor heterogeneity and lineage-specific molecular dependencies. Future research should focus on identifying novel biomarkers, optimizing treatment strategies through multiomic analyses, and leveraging innovative clinical trial designs to advance precision oncology. In particular, further investigation into TILs as a predictive biomarker for immunotherapy is warranted, given their distinct immunophenotypic features and prognostic significance in shaping treatment responses across cancer types.</p> Graphical Abstract <p>Abbreviations: ADC, antibody–drug conjugate; AKT, protein kinase B; ALK, anaplastic lymphoma kinase; APC, antigen-presenting cell; B7-H3, B7 homolog 3; BRAF, B-raf proto-oncogene; CTLA-4: cytotoxic T-lymphocyte-associated protein 4; DNA, deoxyribonucleic acid; ERK, extracellular signal-regulated kinase; FGFR, fibroblast growth factor receptor; GzmB, granzyme B; HER, human epidermal growth factor receptor; IFNγ, interferon-gamma; KRAS, Kirsten rat sarcoma viral oncogene homolog; MEK, mitogen-activated protein kinase kinase; MET, mesenchymal-epithelial transition factor; MSI, microsatellite instability; mTOR, mechanistic target of rapamycin; NRG1, neuregulin 1; NTRK, neurotrophic tyrosine receptor kinases; PD-1, programmed death receptor-1; PFN, perforin; PI3K, phosphoinositide 3-kinase; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; RET, rearranged during transfection; ROS1, proto-oncogene receptor tyrosine kinase 1; T-DXd, fam-trastuzumab deruxtecan-nxki; TIL, tumor-infiltrating lymphocytes; TKI, tyrosine kinase inhibitor; TMB, tumor mutation burden; TNFα, tumor necrosis factor-alpha.</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tissue-agnostic biomarkers in solid tumors: current approvals and emerging candidates

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月27日

查看全文
  • Kim Jinah,
  • Kim Hye Sung,
  • Nam Myungwoo,
  • Chae Young Kwang

摘要

The landscape of cancer treatment has shifted from histology-specific to tissue-agnostic approaches, targeting molecular alterations regardless of tumor origin. Currently, six pan-cancer biomarkers—NTRK, BRAF V600E, RET, HER2-positive, MSI-high, and TMB-high—along with nine molecularly targeted therapies have expanded treatment options across diverse malignancies. This review examines each biomarker’s molecular basis, prevalence across tumor types, and corresponding FDA-approved therapies. Additionally, emerging candidates—including FGFR, ALK, MET, ROS1, NRG1, PIK3CA, AKT, KRAS G12C, HER2 mutations, HER2-low/ultralow, B7-H3, and tumor-infiltrating lymphocytes (TILs)—are explored. While these biomarkers represent a paradigm shift in oncology, their integration into clinical practice requires overcoming challenges related to tumor heterogeneity and lineage-specific molecular dependencies. Future research should focus on identifying novel biomarkers, optimizing treatment strategies through multiomic analyses, and leveraging innovative clinical trial designs to advance precision oncology. In particular, further investigation into TILs as a predictive biomarker for immunotherapy is warranted, given their distinct immunophenotypic features and prognostic significance in shaping treatment responses across cancer types.

Graphical Abstract

Abbreviations: ADC, antibody–drug conjugate; AKT, protein kinase B; ALK, anaplastic lymphoma kinase; APC, antigen-presenting cell; B7-H3, B7 homolog 3; BRAF, B-raf proto-oncogene; CTLA-4: cytotoxic T-lymphocyte-associated protein 4; DNA, deoxyribonucleic acid; ERK, extracellular signal-regulated kinase; FGFR, fibroblast growth factor receptor; GzmB, granzyme B; HER, human epidermal growth factor receptor; IFNγ, interferon-gamma; KRAS, Kirsten rat sarcoma viral oncogene homolog; MEK, mitogen-activated protein kinase kinase; MET, mesenchymal-epithelial transition factor; MSI, microsatellite instability; mTOR, mechanistic target of rapamycin; NRG1, neuregulin 1; NTRK, neurotrophic tyrosine receptor kinases; PD-1, programmed death receptor-1; PFN, perforin; PI3K, phosphoinositide 3-kinase; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; RET, rearranged during transfection; ROS1, proto-oncogene receptor tyrosine kinase 1; T-DXd, fam-trastuzumab deruxtecan-nxki; TIL, tumor-infiltrating lymphocytes; TKI, tyrosine kinase inhibitor; TMB, tumor mutation burden; TNFα, tumor necrosis factor-alpha.